Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Mylan moves...

    Mylan moves application with DCGI to launch new TB drug Pretomanid in India

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-16T16:10:37+05:30  |  Updated On 16 Aug 2021 11:21 AM IST

    "We have submitted the new drug application to the office of DCGI. We are in an advanced stage of discussion and are working with the office of DCGI... Mylan will be in a position to launch the product in India soon after receiving approvals from DCGI," Mylan's global president and executive director Rajiv Malik told PTI during his recent visit to India.


    HYDERABAD: Multinational pharmaceutical company Mylan is working with Drug Controller General of India (DCGI) to launch Pretomanid, a medicine used to treat drug-resistant tuberculosis (TB), a top official of the US drug major has said.


    Non-profit drug developer TB Alliance and Mylan NV had in April announced a global collaboration to make the experimental drug Pretomanid for curing of pulmonary tuberculosis.


    "We have submitted the new drug application to the office of DCGI. We are in an advanced stage of discussion and are working with the office of DCGI... Mylan will be in a position to launch the product in India soon after receiving approvals from DCGI," Mylan's global president and executive director Rajiv Malik told PTI during his recent visit to India.


    This drug is important for India because Prime Minister Narendra Modi said India would get rid of tuberculosis by 2025, he added.


    Also, Modi launched a campaign to eradicate TB from India by 2025, five years ahead of a globally-set deadline.


    TB Alliance was currently advancing the development of Pretomanid in three ongoing late-stage clinical trials, Mylan had said in April.


    Also Read: Mylan, TB Alliance to commercialize Pretomanid to treat TB


    Pretomanid is only the third new anti-TB drug approved for use by the US Food and Drug Administration (FDA) in more than 40 years and is the first to be developed and registered by a not-for-profit organisation.


    Mylan expects the drug to be launched in the USA during this year-end, he said.


    The United States will be the first country in which the product will be launched, and we expect this to occur by the end of this year. In other countries with a high TB burden, Mylan is in the process of filing for registration of Pretomanid with various regulatory authorities, the official said.


    Tuberculosis continues to be one of the top 10 causes of death worldwide and the leading infectious killer-disease.


    India has the worlds highest share (27 per cent) of all TB cases at 2.7 million and accounted for nearly a third of all TB deaths in 2017. A total of 21.5 lakh TB cases was reported in 2018, an increase of 17 per cent over 18 lakh in 2017, as per the Annual India TB Report for 2019 released recently, a Mylan spokesperson said.


    Also Read: Cutting TB drugs prices in India: Johnson and Johnson, Mylan propose ways
    DCGIDrug Controller General of IndiaIndiaModiMylanNarendra Modipharmapharma newspharma news indiaPm of indiapretomanidpulmonary tuberculosisTBTB AllianceTB drugTuberculosisUS Food and Drug AdministrationUSFDAUSFDA approved
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok